Ligand Pharmaceuticals Inc. (LGND) is a publicly traded Healthcare sector company. As of May 21, 2026, LGND trades at $217.75 with a market cap of $4.17B and a P/E ratio of 27.80. LGND moved +4.88% today. Year to date, LGND is +13.39%; over the trailing twelve months it is +107.54%. Its 52-week range spans $93.58 to $247.38. Analyst consensus is strong buy with an average price target of $279.71. Rallies surfaces LGND's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What do analysts rate LGND?
7 analysts cover LGND: 0 strong buy, 7 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $279.71.
KOZARICH JOHN W sold 1.57K (~$352.01K) on May 13, 2026.
KOZARICH JOHN W sold 459 (~$102.82K) on May 12, 2026.
KOZARICH JOHN W sold 80 (~$18.19K) on May 1, 2026.
Common questions about LGND
What do analysts rate LGND?
7 analysts cover LGND: 0 strong buy, 7 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $279.71.
Does Rallies show LGND price targets?
Yes. Rallies tracks LGND analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is LGND research on Rallies investment advice?
No. Rallies provides research, data, and educational context for LGND. It does not provide personalized investment advice.